Lelia H Chaisson1, Valeria Saraceni, Silvia Cohn, Dena Seabrook, Solange C Cavalcante, Richard E Chaisson, Jonathan E Golub, Betina Durovni. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Municipal Health Secretariat, Rio de Janeiro, Brazil Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland Linksbridge SPC, Seattle, Washington, USA Instituto Nacional de Infectologia Evandro Chagas Centro de Estudos Estratégicos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Abstract
OBJECTIVES: In 2018, Brazilian guidelines changed to recommend tuberculosis (TB) preventive therapy for all people with HIV and a CD4 cell count 350 cells/μl or less, but only for those with a positive tuberculin skin test (TST) if CD4 cell count is than 350 cells/μl. We determined the potential effectiveness of CD4-based guidelines for TB testing and preventive therapy. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT). METHODS: We analyzed data from 4114 newly registered patients with HIV in 29 clinics followed until TB diagnosis, death, or administrative censoring. We compared incidence rates of TB and TB/death between CD4, TST, IPT, and antiretroviral therapy categories. RESULTS: Initial CD4 cell count was 350 cells/μl or less in 2138 (52%) and more than 350 cells/μl in 1976 (48%) patients. TST was performed for 2922 (71%), of whom 657 (16%) were TST-positive [278 (13%) CD4 ≤ 350 vs. 379 (19%) CD4 > 350]. A total of 619 (15%) received IPT and 2806 (68%) received antiretroviral therapy. For patients with CD4 cell count 350 cells/μl or less who did not receive IPT, the incidence rate of TB was 1.79/100 person-years (pys) and TB/death was 3.89/100 pys. For patients with CD4 cell count more than 350 who did not receive IPT, the incidence rates of TB and TB/death were 0.57/100 and 1.49/100 pys for TST-negatives, and 1.05/100 and 1.64/100 pys for TST-unknowns. CONCLUSION: TB incidence was high among all patients who did not receive IPT, including those with CD4 cell count more than 350 cells/μl and negative or unknown TST results. TB preventive therapy should be provided to all people living with HIV in medium burden settings, regardless of CD4 cell count and TST status.
OBJECTIVES: In 2018, Brazilian guidelines changed to recommend tuberculosis (TB) preventive therapy for all people with HIV and a CD4 cell count 350 cells/μl or less, but only for those with a positive tuberculin skin test (TST) if CD4 cell count is than 350 cells/μl. We determined the potential effectiveness of CD4-based guidelines for TB testing and preventive therapy. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT). METHODS: We analyzed data from 4114 newly registered patients with HIV in 29 clinics followed until TB diagnosis, death, or administrative censoring. We compared incidence rates of TB and TB/death between CD4, TST, IPT, and antiretroviral therapy categories. RESULTS: Initial CD4 cell count was 350 cells/μl or less in 2138 (52%) and more than 350 cells/μl in 1976 (48%) patients. TST was performed for 2922 (71%), of whom 657 (16%) were TST-positive [278 (13%) CD4 ≤ 350 vs. 379 (19%) CD4 > 350]. A total of 619 (15%) received IPT and 2806 (68%) received antiretroviral therapy. For patients with CD4 cell count 350 cells/μl or less who did not receive IPT, the incidence rate of TB was 1.79/100 person-years (pys) and TB/death was 3.89/100 pys. For patients with CD4 cell count more than 350 who did not receive IPT, the incidence rates of TB and TB/death were 0.57/100 and 1.49/100 pys for TST-negatives, and 1.05/100 and 1.64/100 pys for TST-unknowns. CONCLUSION: TB incidence was high among all patients who did not receive IPT, including those with CD4 cell count more than 350 cells/μl and negative or unknown TST results. TB preventive therapy should be provided to all people living with HIV in medium burden settings, regardless of CD4 cell count and TST status.
Authors: A L Pozniak; K M Coyne; R F Miller; M C I Lipman; A R Freedman; L P Ormerod; M A Johnson; S Collins; S B Lucas Journal: HIV Med Date: 2011-10 Impact factor: 3.180
Authors: Mina C Hosseinipour; Gregory P Bisson; Sachiko Miyahara; Xin Sun; Agnes Moses; Cynthia Riviere; Fredrick K Kirui; Sharlaa Badal-Faesen; David Lagat; Mulinda Nyirenda; Kogieleum Naidoo; James Hakim; Peter Mugyenyi; German Henostroza; Paul D Leger; Javier R Lama; Lerato Mohapi; Jorge Alave; Vidya Mave; Valdilea G Veloso; Sandy Pillay; Nagalingeswaran Kumarasamy; Jing Bao; Evelyn Hogg; Lynne Jones; Andrew Zolopa; Johnstone Kumwenda; Amita Gupta Journal: Lancet Date: 2016-03-19 Impact factor: 79.321
Authors: Betina Durovni; Valeria Saraceni; Lawrence H Moulton; Antonio G Pacheco; Solange C Cavalcante; Bonnie S King; Silvia Cohn; Anne Efron; Richard E Chaisson; Jonathan E Golub Journal: Lancet Infect Dis Date: 2013-08-16 Impact factor: 25.071
Authors: Miguel Santin; Susana Casas; Maria Saumoy; Ana Andreu; Raquel Moure; Fernando Alcaide; Elena Ferrer; Daniel Podzamczer Journal: Diagn Microbiol Infect Dis Date: 2011-01 Impact factor: 2.803
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: Molebogeng Xheeda Rangaka; Katalin A Wilkinson; Ronnett Seldon; Gilles Van Cutsem; Graeme Ayton Meintjes; Chelsea Morroni; Priscilla Mouton; Lavanya Diwakar; Tom G Connell; Gary Maartens; Robert J Wilkinson Journal: Am J Respir Crit Care Med Date: 2006-12-07 Impact factor: 21.405
Authors: Molebogeng X Rangaka; Robert J Wilkinson; Andrew Boulle; Judith R Glynn; Katherine Fielding; Gilles van Cutsem; Katalin A Wilkinson; Rene Goliath; Shaheed Mathee; Eric Goemaere; Gary Maartens Journal: Lancet Date: 2014-05-13 Impact factor: 79.321
Authors: Lelia H Chaisson; Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Richard E Chaisson; Betina Durovni; Jonathan E Golub Journal: J Acquir Immune Defic Syndr Date: 2021-12-01 Impact factor: 3.771